Search results for Indatuximab
Indatuximab, Abbexa, abx831233
Indatuximab is a monoclonal antibody biosimilar expressed in CHO cells, targeting SDC1/CD138, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Host
Human, Mouse
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Indatuximab ELISA Kit, Abbexa, abx395094
Indatuximab ELISA Kit is a quantitative ELISA kit for detection of Indatuximab.Indatuximab ravtansine (BT062) is an antibody-drug conjugate (ADC) based on a murine/human chimeric form of B-B4 (CD138-specific antibody), which is covalently conjugated to the maytansinoid drug DM4 via a disulfide bond-based linker. Maytansinoids are structural analogs of the cytotoxic agent maytansine, which has been evaluated in phase I and phase II clinical trials. They exhibit anti-mitotic activity by inducing metaphase arrest of dividing cells, causing cell death. Upon internalization of indatuximab ravtansine by target tumor cells, lysosomal processing of the disulfide linker generates a lysine metabolite which is reduced and S-methylated producing the lipophilic and cytotoxic metabolite, S-methyl-DM4. The mechanism of action of indatuximab ravtansine resembles that of trastuzumab emtansine, an antibody-drug conjugate indicated for HER2-positive metastatic breast cancer which uses the HER2-targeting properties of trastuzumab to deliver the cytotoxic DM1 within the cell by means of a stable linker. The intracellular drug delivery to target tumor cells can improve the therapeutic index of the cytotoxic drug and minimize exposure of normal tissue. Indatuximab ravtansine has previously been shown in vivo in multiple myeloma mouse xenograft models to significantly inhibit tumor growth and prolong host survival without any toxicity signals. Based on these preclinical results, a phase I clinical trial of indatuximab ravtansine demonstrated the first signs of clinical activity in patients with relapsed or refractory multiple myeloma without any toxicity signals. Furthermore, preliminary data from a phase I/IIa study in relapsed or refractory multiple myeloma indicated that indatuximab ravtansine is well tolerated even in a multiple-dose schedule and provided further evidence of clinical activity. Indatuximab ravtansine is being investigated as part of a treatment for multiple myeloma.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Indatuximab ELISA Kit, ProteoGenix, KPTX205
Description of Indatuximab ELISA Kit Introduction Indatuximab is a monoclonal antibody that has shown promising results in the treatment of multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow. It works by targeting a specific protein, making it a valuable therapeutic target for this disease. The use of Indatuximab is supported by the availability of an ELISA kit, which allows for the accurate and sensitive measurement of this antibody in biological samples. In this article, we will explore the structure, activity, and application of Indatuximab ELISA kit in detail. Structure of Indatuximab Indatuximab is a chimeric monoclonal antibody, meaning it is composed of both human and mouse components. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for the antibody’s specificity and binds to its target, while the constant region is responsible for the antibody’s effector functions. Indatuximab specifically targets a protein called CD138, which is highly expressed on the surface of multiple myeloma cells. Activity of Indatuximab Indatuximab works by binding to CD138 on the surface of multiple myeloma cells, triggering a series of events that ultimately lead to the destruction of these cancerous cells. The binding of Indatuximab to CD138 activates the immune system, causing immune cells to recognize and attack the cancer cells. This process is known as antibody-dependent cellular cytotoxicity (ADCC), and it is one of the main mechanisms of action of Indatuximab. In addition to ADCC, Indatuximab also has the ability to induce apoptosis, or programmed cell death, in multiple myeloma cells. This is achieved through the activation of a signaling pathway known as the caspase cascade, which ultimately leads to the death of the cancer cells. This dual mechanism of action makes Indatuximab a potent and effective therapeutic agent for the treatment of multiple myeloma. Application of Indatuximab ELISA Kit The availability of an ELISA kit for Indatuximab has greatly facilitated its use in clinical settings. The kit allows for the accurate and sensitive measurement of Indatuximab levels in biological samples, such as blood or serum. This is important for monitoring the effectiveness of treatment and ensuring that patients are receiving the appropriate dosage of Indatuximab. The Indatuximab ELISA kit is also useful in research settings, as it allows for the quantification of Indatuximab in preclinical studies. This can help in the development of new treatment strategies and in understanding the mechanisms of action of this antibody. Furthermore, the Indatuximab ELISA kit can also be used to measure the presence of anti-drug antibodies (ADAs) in patients receiving Indatuximab treatment. ADAs can potentially reduce the effectiveness of the treatment and may lead to adverse reactions. The use of the ELISA kit allows for the early detection of ADAs, allowing for prompt intervention and adjustment of treatment if necessary. Conclusion Indatuximab is a promising therapeutic agent for the treatment of multiple myeloma, and its effectiveness is supported by the availability of an ELISA kit. The structure of Indatuximab, with its dual mechanism of action, makes it a potent and specific antibody for targeting CD138. The Indatuximab ELISA kit is a valuable tool in monitoring treatment effectiveness, understanding the mechanisms of action, and detecting potential adverse reactions in patients. With ongoing research and development, Indatuximab and its ELISA kit have the potential to greatly improve the outcomes for patients with multiple myeloma.
Host
Reactivity
Applications
Conjugation
Indatuximab Biosimilar - Research Grade, ichor.bio, ICH5246
Detects human SDC1
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.